Navigation Links
Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Date:4/29/2009

STOCKHOLM, Sweden, April 29 /PRNewswire/ --

- Results to be Presented at World Congress of Nephrology 2009

Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease. Nefecon is an enteric formulation of a locally acting corticosteroid which downregulates the inflammatory process in the kidneys through suppression of the gut immune system.

Sixteen patients at trial centers in Sweden were treated for six months followed by a three month follow up period. Full results will be presented at the World Congress of Nephrology 2009, 22-26 May in Milan (Smerud et al, Enteric Budesonide Ameliorates Albuminuria and Glomerular Filtration Rate in IgA Nephropathy Patients) and at the satellite meeting, IgA Nephropathy, 26-28 May in Stresa, Italy.

"It is very gratifying to have completed this important stage in the development of Nefecon," said Johan Haggblad, Managing Director of Pharmalink. "We hope to bring a new licensed treatment where other therapies have failed and will now focus on preparing for pivotal trials and on seeking a development partner to bring Nefecon through Phase III and to the market."

Nefecon is being co-developed by Pharmalink and Archimedes Development Ltd ("Archimedes") a subsidiary of Archimedes Pharma Ltd under a partnership agreed in January 2004 to bring the product candidate to proof-of-concept. The concept underlying the renal disease product candidate Nefecon is a patented invention by Professors Bengt Fellstrom and Roger Hallgren at Uppsala University, Sweden. It is delivered using Archimedes' proprietary TARGIT(R) drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gut. Archimedes is providing access to the TARGIT platfor
'/>"/>

SOURCE Pharmalink AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
3. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
6. Gen-Probe Completes Acquisition of Tepnel Life Sciences
7. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
8. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
9. Atritech Completes $30 Million Financing
10. Roche Completes Tender Offer for Genentech
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Jan. 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... criteria to proceed to full enrolment in its ... of REOLYSIN(R) in patients with,various sarcomas that have ... trial protocol, to proceed to full enrolment of ...
... blueprint of all life, giving instruction and function to ... beings. Now Northwestern University researchers report they have used ... build a three-dimensional structure out of gold, a lifeless ... the researchers built two common but very different crystalline ...
... 19.8% Revenue Growth -, PRINCETON, N.J., Jan. 30 ... fourth quarter ended December 31, 2007,of $0.78 per diluted ... $0.06 per share gain from the sale of its ... $0.72 per diluted share in the,fourth quarter, representing 21.8% ...
Cached Biology Technology:Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 2Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 3DNA is blueprint, contractor and construction worker for new structures 2DNA is blueprint, contractor and construction worker for new structures 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 2Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 4Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 5Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 6Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 7Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 8Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 9Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 10Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 11
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/15/2014)... NEW YORK , Nov. 13, 2014  While we ... of technology Doctor McCoy used in "Star Trek" to gain ... and tools designed to work with smartphones and tablets for ... corners of the healthcare world. This may seem a tad ... are ready to adopt some of these technological opportunities into ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... using a novel technique to better understand mineral growth ... Ridge National Laboratory are improving predictions of mineral reactions ... oil pipes clear to sequestering radium. The mineral ... generally, but also because it is the dominant scale-forming ...
... SUNY Downstate Medical Center,s growth into a major center ... awarded SUNY Downstate a four-year challenge grant of $220,000 ... causes, treatment, and prevention of blinding diseases. Douglas R. ... principal investigator. RPB is the world,s leading voluntary organization ...
... one of the most common neurological diseases, more than 4,000 ... decoded over the next five years in a study led ... and several collaborating institutions. Daniel Lowenstein, MD , ... been attempted for identifying the genetic causes of epilepsy, and ...
Cached Biology News:Metadynamics technique offers insight into mineral growth and dissolution 2SUNY Downstate receives grant from research to prevent blindness 2UCSF shares $25-million grant to find epilepsy genes 2UCSF shares $25-million grant to find epilepsy genes 3
... system, 220-240 V, is used for nucleic acid ... slab gel format. The system includes the modular ... separating nucleic acids with single base-pair resolution and ... and bonded inner glass plate, outer glass plate, ...
... PowerPac HV high-voltage power supply, with temperature probe, ... of 5,000 V, 500 mA, and 400 W. ... temperature between 0 and 90 degrees C during ... transfer. Power cord and instructions are provided. Dimensions ...
... cooling coil, Trans-Blot cell, provides ... high-intensity, and extended electrophoretic transfer ... Trans-Blot cell. Use of the ... to an external water recirculator, ...
... By incorporating a wide range of next-generation ... sets a new standard for flexible laboratory ... handling including pipetting, dilution, dispensing, and ... thats as powerful and flexible as it ...
Biology Products: